Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials

Jiang Li; Jian-cheng Wang; Bin Ma; Wei Gao; Peng Chen; Rao Sun; Ke-hu Yang

doi:10.1007/s11655-014-1768-8

Your Location：

Home >

Browse articles >

Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials

Updated：2021-08-27

- Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials
- Chinese Journal of Integrative Medicine Vol. 21, Issue 1, Pages: 71-79(2015)
- Affiliations：
  
  1. Evidence-Based Medicine Center, College of Basic Medicine, Lanzhou University,Lanzhou,China
  2. Institute of Integrated Traditional Chinese and Western Medicine, College of Basic Medicine, Lanzhou University,Lanzhou,China
  3. Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province,Lanzhou,China
  4. Department of Internal Medicine, University of California Davis Medical Center, Sacramento,USA
  5. First School of Clinical Medicine, Guangzhou University of Chinese Medicine,Guangzhou,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-014-1768-8
  CLC：
- Published：2015，
  
  Published Online：23 September 2014，
Scan for full text
Li, J., Wang, Jc., Ma, B. et al. Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials., Chin. J. Integr. Med. 21, 71–79 (2015). https://doi.org/10.1007/s11655-014-1768-8

Jiang Li, Jian-cheng Wang, Bin Ma, et al. Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials. [J]. Chinese Journal of Integrative Medicine 21(1):71-79(2015)
Li, J., Wang, Jc., Ma, B. et al. Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials., Chin. J. Integr. Med. 21, 71–79 (2015). https://doi.org/10.1007/s11655-014-1768-8 DOI：

Jiang Li, Jian-cheng Wang, Bin Ma, et al. Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials. [J]. Chinese Journal of Integrative Medicine 21(1):71-79(2015) DOI： 10.1007/s11655-014-1768-8.

摘要

To evaluate the effectiveness of Shenqi Fuzheng Injection (参芪扶正注射液

SFI) combined with chemotherapy for advanced gastric cancer. Randomized controlled trials (RCTs) from 10 databases were searched for this meta-analysis till December 31

2012 without language restriction. Grey literature and potential unpublished literature was also searched. The key search terms were “chemotherapy”

“Shenqi Fuzheng Injection” and “advanced gastric cancer”. Criteria were built to select these clinical trials

in which SFI combined with chemotherapy was compared with chemotherapy alone for advanced gastric cancer. The methodological quality of each RCT was assessed using the Cochrane risk of bias tool. RevMan 5.1 software was applied for data analyses. Thirteen RCTs involving 860 patients met the selection criteria (all articles were from Chinese databases). The meta-analysis showed positive results for the use of SFI combined with chemotherapy according to quality of life in terms of the scores when compared with chemotherapy alone. Positive results were also obtained for the combination treatment

in terms of complete remission and partial remission efficacy rate

body weight and decreased adverse events including nausea and vomiting at grade 3–4

oral mucositis at grade 1–2

leucopenia at grade 3–4

and myelo-suppression at grade 1–2. This systematic review found encouraging albeit limited evidence for SFI combined with chemotherapy. However

to obtain stronger evidence without the drawbacks of trial design and the quality of studies

we recommend comparative effectiveness researches to test the effectiveness of combination treatment.

Abstract

To evaluate the effectiveness of Shenqi Fuzheng Injection (参芪扶正注射液

SFI) combined with chemotherapy for advanced gastric cancer. Randomized controlled trials (RCTs) from 10 databases were searched for this meta-analysis till December 31

2012 without language restriction. Grey literature and potential unpublished literature was also searched. The key search terms were “chemotherapy”

“Shenqi Fuzheng Injection” and “advanced gastric cancer”. Criteria were built to select these clinical trials

in terms of complete remission and partial remission efficacy rate

body weight and decreased adverse events including nausea and vomiting at grade 3–4

oral mucositis at grade 1–2

leucopenia at grade 3–4

and myelo-suppression at grade 1–2. This systematic review found encouraging albeit limited evidence for SFI combined with chemotherapy. However

to obtain stronger evidence without the drawbacks of trial design and the quality of studies

we recommend comparative effectiveness researches to test the effectiveness of combination treatment.

关键词

chemotherapyShenqi Fuzheng injectionadvanced gastric cancerChinese Medicinesystematic reviewrandomized controlled trial

Keywords

chemotherapyShenqi Fuzheng injectionadvanced gastric cancerChinese Medicinesystematic reviewrandomized controlled trial

references

Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 2009;21:381–385.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.

Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006;20:633–649.

Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33–64.

Sun DZ, Jiao JP, Ju DW, Ye M, Zhang X, Xu JY, et al. Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of “tumor-phlegm micro-environment”. Chin J Integr Med 2012;18:350–358.

Park JW, Yoon J, Cho CK, Lee YW, Yoo HS. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus. Chin J Integr Med 2014;20:49–55.

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophagogastric cancer: a randomised phase II study. Br J Cancer 2012;107:435–441.

Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441–1447.

Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Costeffectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010;116:2941–2953.

Acupuncture stimulated healing. http://www.koreatimes.co.kr/www/news/art/2009/10/153_38654.html

Dharmananda S. Kampo medicine: the practice of Chinese herbal medicine in Japan. Portland, OR: Institute for Traditional Medicine; 2001.

Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO. The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 2008;14:1049–1055.

McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006;24:419–430.

Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage 2000;20:374–387.

Lu Y, Lu YX. Clinical application and pharmacology function of Shenqi Fuzheng Injection. Lishizhen Med Mater Med Res (Chin) 2006;17:2083–2085.

Sheng S, Song M. The component analysis of Shengqi Fuzheng Injection. J China Prescript Drug (Chin) 2004;8:47–49.

Pan L. Practical road of “the numeral turn Chinese herbal medicine” for Shenqi Fuzheng Injection. J China Prescript Drug (Chin) 2009;1:37–39.

Zhong ZH. Dictate history: a national new medicine that come from experiential prescription. J China Prescript Drug (Chin) 2009;1:33–36.

Hollen PJ, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994;73:2087–2098.

Zhou HJ, So JB, Yong WP, Luo N, Zhu F, Naidoo N, et al. Validation of the functional assessment of cancer therapy—gastric module for the Chinese population. Health Qual Life Outcomes 2012;10:145.

National Cancer Institute. Common terminology criteria for adverse events and common toxicity criteria. Version 4.0. Bethesda: NCI; 2010. http://ctep.cancer.gov/protocolDevelopment/electronicapplications/ctc.htm#ctc_40.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.

Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42–46.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–926.

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in metaanalyses? Lancet 1998;352:609–613.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.

Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Fang XY. Observation of efficacy of Shenqi Fuzheng Injection combined with FOLFOX4 chemotherapy in treatment of advanced gastric cancer. Chin J Pract Med (Chin) 2010;37:23–24.

Jia JW, Liu YQ. Effect of Shenqi Fuzheng Injection combined with FOLFOX4 regimen in the treatment of advanced gastric cancer. Pract J Cancer (Chin) 2009;24:273–275.

Li ZY, Huang QH, Xu HS, Ruan XF. The efficacy of Shenqi Fuzheng Injection combined with chemotherapy in gastric cancer. J Liaoning Univ Tradit Chin Med (Chin) 2006;8:26–27.

Liu H, Han D. Effects of Shenqi Fuzheng Injection on the immunolologic function and clinic efficacy in the elderly patients with advanced gastric cancer. Chin J Clin Pharmacol (Chin) 2011;27:177–183.

Luo PF. The efficacy of Shenqi Fuzheng Injection combination chemotherapy for advanced gastric cancer. Modern Med Health (Chin) 2011;27:1170–1171.

Wan LX, Wang Y. Shenqi Fuzheng Injectiong combined with FOLFOX4 for advanced gastric cancer. J Med Forum (Chin) 2006;27:96–97.

Wang JF. Shenqi Fuzheng Injection combined chemoradiotherapy treatment of locally advanced gastric cancer. Chin Med Sci Technol (Chin) 2010;17:537–538.

Wang M, Lin HJ. Efficacy observation of Shenqi Fuzheng Injection combined with FOLFOX4 chemotherapy in treatment of advanced gastric cancer. Drugs Clin (Chin) 2011;18:89–90.

Wang YS, Shi ZX, Guo YH. Shenqi Fuzheng Injection combination chemotherapy for elderly patients with advanced gastric cancer. Med J West Chin (Chin) 2011;23:1958–1959.

Xiong W. The efficacy Shenqi Fuzheng Injection with DCF chemotherapy in advanced gastric cancer. Guangming Chin Med (Chin) 2010;25:635–636.

Yue CL. Clinical observation of chemotherapy combined with Shenqi Fuzheng Injection treating gastric cancer. Chin New Med (Chin) 2003;4:1063–1064.

Zhao JM, Wu AZ, Shi LR, Yang XX, Li JH, Wu CP. Clinical observation on treatment of advanced gastric cancer by combined use of Shenqi Fuzheng Injection, docetaxel, flurouracil and calcium folinate. Chin J Integr Tradit West Med (Chin) 2007;27:736–738.

Zhou KX, Wang JH, Liu BK, Zhou CY, Xin M, Zhi JL, et al. Clinical study on effect of Shenqi Fuzheng Injection combined with chemotherapy in treating gastric cancer. Chin J Integr Tradit West Med (Chin) 1999;19:11–13.

Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun 2004;320:1103–1111.

Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614–618

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials

Efficacy of externally applied Chinese herbal drugs in treating psoriasis: A systematic review

Efficacy and safety of Flos Abelmoschus manihot (Malvaceae) on type 2 diabetic nephropathy: A systematic review

Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis

Toward Evidence-Based Chinese Medicine: Status Quo, Opportunities and Challenges

Related Author

No data

Related Institution

Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences

The First Hospital of Beijing University of Chinese Medicine

Department of Dermatology, China-Japan Friendship Hospital, Beijng

Janssen Pharmaceutical Ltd., Beijing

Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰